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Abstract
Background:  All-trans retinoic acid (RA) is one of the most important morphogens with
pleiotropic actions. Its embryonic distribution correlates with neural differentiation in the
developing central nervous system. To explore the precise effects of RA on neural differentiation
of mouse embryonic stem cells (ESCs), we detected expression of RA nuclear receptors and RA-
metabolizing enzymes in mouse ESCs and investigated the roles of RA in adherent monolayer
culture.
Results: Upon addition of RA, cell differentiation was directed rapidly and exclusively into the
neural lineage. Conversely, pharmacological interference with RA signaling suppressed this neural
differentiation. Inhibition of fibroblast growth factor (FGF) signaling did not suppress significantly
neural differentiation in RA-treated cultures. Pharmacological interference with extracellular signal-
regulated kinase (ERK) pathway or activation of Wnt pathway effectively blocked the RA-promoted
neural specification. ERK phosphorylation was enhanced in RA-treated cultures at the early stage
of differentiation.
Conclusion:  RA can promote neural lineage entry by ESCs in adherent monolayer culture
systems. This effect depends on RA signaling and its crosstalk with the ERK and Wnt pathways.
Background
Embryonic stem cells (ESCs) are self-renewable and show
a pluripotent ability to differentiate into cellular deriva-
tives of all three primary germ layers. They are considered
to be a unique biological system for disclosing the mech-
anisms of pluripotency and lineage commitment, and a
useful material for disease modeling, pharmacological
screening, and cell therapy.
All-trans retinoic acid (RA), which is a metabolic product
of vitamin A (retinol), is one of the most important mor-
phogens but with pleiotropic actions  it induces develop-
ment of several lineages [1]. RA is an established signaling
molecule involved in neuronal patterning, neural differ-
entiation and axon outgrowth [2]. It is of great importance
to understand well the mechanism of action of RA on the
development of the nervous system. RA is known to be
Published: 30 July 2009
BMC Cell Biology 2009, 10:57 doi:10.1186/1471-2121-10-57
Received: 17 November 2008
Accepted: 30 July 2009
This article is available from: http://www.biomedcentral.com/1471-2121/10/57
© 2009 Lu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cell Biology 2009, 10:57 http://www.biomedcentral.com/1471-2121/10/57
Page 2 of 15
(page number not for citation purposes)
capable of inducing ESCs to differentiate into neurons
within embryoid bodies (EBs) in vitro [3-5]. However, the
route by which RA influences neural commitment is still
obscure. Furthermore, it is difficult to dissect and manip-
ulate differentiation within EBs because they are multicel-
lular agglomerations of extra-embryonic endoderm and
definitive ectodermal, mesodermal and endodermal
derivatives [6].
In this study, we used a monolayer culture system of neu-
ral induction [7] and treated the cultures with low concen-
tration of RA (10-8  M), which ranged between the
physiological (10-9 M) and pharmacological (10-6 M) lev-
els [8]. We found that among RA nuclear receptors  retinoic
acid receptors (RARs) and retinoid × receptors (RXRs), and
RA-metabolizing enzymes (CYP26a1 and Raldh2), only
the mRNAs of RARα, RARγ, RXRβ, Cyp26a1 and Raldh2
were detectable in mouse ESCs. Upon stimulation with
RA, the nuclear receptors and RA-metabolizing enzymes
showed dynamic changes in expression. In RA-treated cul-
tures, the specific marker for ESCs, i.e., Oct4, was down-
regulated more rapidly, and markers for neural cells were
up-regulated sooner than in the other two control groups.
We reported that RA-promoted neural differentiation was
blocked by the RARα-selective antagonist Ro 415253,
which indicates that RA signaling is essential for neural
specification in this monolayer culture system, and RARα
pathway may play a key role in this effect. Furthermore,
our data demonstrated that the process of this enhanced
neural differentiation involved crosstalk between RA and
the extracellular signal-regulated kinase (ERK) and Wnt
pathways.
Results
1. RA causes earlier expression of Sox1 in ESCs
To assess whether RA could promote ESCs entry to the
neural lineage in a monolayer culture system, 46C ESCs
were transferred into a differentiation induction regime
which comprised an adherent monolayer culture without
any exogenous growth factors [9], or with RA or solvent
(0.02% ethanol). It is believed that the first conditions are
permissive for neural commitment driven by autocrine
signaling [7]. During experiments, we found that high
does of RA (10-6 M) showed an obvious noxious effect on
cell survival (see Additional file 1  Figure S1). Therefore,
we treated the cultures with low concentration of RA (10-
8 M), which was between the physiological (10-9 M) and
pharmacological (10-6 M) levels [10].
Cells were harvested and analyzed by flow cytometry for
Sox1GFP expression, which is the earliest known specific
marker of neuroectoderm in the mouse embryo [11]. 46C
ESCs without treatment with any exogenous growth fac-
tors (N2B27+0, control) or after treatment with ethanol
(N2B27+ethanol, solvent control) generated green fluo-
rescent protein (GFP) positive cells progressively after an
initial lag: almost no GFP+ cells were detected after 68 h,
and only 4.6 ± 1.24% (N2B27+0) or 2.5 ± 0.58%
(N2B27+ethanol) after 92 h. In contrast, 10-8  M RA-
treated cultures contained about 1% GFP+ cells at 20 h,
which increased dramatically to 17.2 ± 0.30% at 44 h (Fig-
ure 1C).
10-8 M RA increased the number of cells in the monolayer
culture at the early stage of neural induction (see Addi-
tional file 2  Figure S2). Therefore, it is reasonable to spec-
ulate that RA can also act after specification to increase the
survival and/or proliferation of neural precursors. We cul-
tured cells without RA for 96 h, and then treated the
adherent cultures with RA. We observed an increase in the
number of Sox1GFP+ cells after treatment with RA (Figure
1D). However, it is still hard to judge whether the increase
in Sox1GFP+ cells was caused by the survival and/or prolif-
erative effects of RA on neural precursors or by its neural
differentiation effects on ESCs. Therefore, we obtained
some purified Sox1GFP+ cells by culturing cells without RA
for 6 days and selecting Sox1GFP+ cells by treatment with
0.5 μg/ml puromycin for another 4 days. These purified
Sox1GFP+ cells were treated with or without RA for several
days. After treatment with RA, there was a dramatic
decrease in Sox1GFP+ cells (Figure 1E). Moreover, cultures
at clonal density showed that there were almost no clones
that contained GFP+ cells in control and solvent control
cultures, while more than 80% of clones contained GFP+
cells in RA-treated cultures (Figure 1F). These data sug-
gested that the observed initial increase in frequency of
Sox1GFP-expressing cells was not caused mainly by the sur-
vival and/or proliferative effects of RA on neural precur-
sors but by its neural differentiation effects on ESCs.
To test further whether RA directly promoted ESC differ-
entiation, we examined the cell-density dependence of
neural specification. Neural induction of ESCs during
monolayer differentiation is strongly inhibited by even
modest increases in cell density [9]. Cells treated with 10-
8 M RA generated far fewer Sox1GFP+ neural precursors at
high cell density (3 × 104cells/cm2) than those at low cell
density (1 × 104cells/cm2), while in control and solvent
control cultures, cells almost completely eliminated neu-
ral specification at high density (see Additional file 3  Fig-
ure S3). This suggested that RA affected neural
specification of ESCs also in a cell-density dependent
manner.
We also noted a difference in the variability of GFP inten-
sity between cultures. Control or solvent control cultures
contained a mixture of less intensely GFP+ cells [Figure 1B
(Day5 N2B27+0 and Day5 N2B27+ethanol)], whereas
RA-treated cells showed uniformly moderate GFP expres-
sion [Figure 1B (Day5 N2B27 + 10-8 M RA)].BMC Cell Biology 2009, 10:57 http://www.biomedcentral.com/1471-2121/10/57
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The effects of RA at the onset of ESC differentiation were
indicated by the kinetics and pattern of gene regulation.
One of the key marker genes Oct4 was examined. Oct4, a
critical determinant of the pluripotent state, is down-reg-
ulated early during somatic differentiation [12]. Within 3
days of leukemia inhibitory factor (LIF) and serum with-
drawal, Oct4 mRNA decreased dramatically in RA-treated
cells, while there was a smaller decrease in control or sol-
vent control cells; after day 3, almost no Oct4 expression
was observed in RA-treated cultures (Figure 1GI).
In summary, these data indicated that RA acted at the ini-
tial stages of ESC differentiation to promote the transition
into neuroectoderm.
2. RA facilitates emergence of neural progenitors, neural 
stem cells and neurons
To ensure that RA indeed accelerated neural specification,
we assayed multiple markers of neural progenitors, neural
stem cells and neurons by RT-PCR and Q-PCR (Figure
2AC).  Pax6  (a marker for neuroectoderm) and Nestin
(which is expressed in undifferentiated neural progeni-
tors) were detected readily in RA-treated cultures at day 3,
while no obvious expression was found in control and
solvent control cultures. Other markers of neural stem/
progenitor cells, such as BLBP (brain lipid binding pro-
tein) (a marker of more mature neural precursors), Olig2
(a basic-helix-loop-helix transcription factor that is
expressed in most ventral neural progenitor cells around
the period of neural tube closure [13]) and Musashi
(which encodes an RNA-binding protein), were all
expressed earlier in RA-treated cultures. Tuj1 (a marker of
immature neurons), NCAM (neural cell adhesion mole-
cule) (a nonexclusive neural marker) and MAP2 (microtu-
bule associated protein 2) (a marker of mature neurons),
were also expressed earlier in RA-treated cultures than in
control or solvent control cultures.
We also used fluorescence microscopy and western blot to
monitor the expression of markers for neural stem cells,
neurons and glia. At day 3, with the rapid disappearance
of Oct4+ cells, Sox1GFP+ and Nestin+ cells were found in
RA-treated cultures (Figure 2D). The expression of Tuj1
was upregulated at day 6 in RA-treated cultures, while 3
days later, Tuj1+ cells appeared in control and solvent
control cultures (Figure 2E and 2F). With the accelerated
emergence of neural stem cells and immature neurons,
the expression of Neuronal nuclei (NeuN; a vertebrate
neuron-specific nuclear protein) and glial fibrillary acidic
protein (GFAP; a marker of glia cells) was also upregu-
lated, and MAP2+ and GFAP+ cells also appeared earlier
in RA-treated cultures (Figure 2EG). At day 11, in control
and solvent control cultures, most cells were Nestin+ and
were in the rosette conformations that is typical of neu-
roepithelial cells (Figure 2Gg and 2Gh), whereas in RA-
treated cultures, although Nestin+ cells were still distrib-
uted in the rosette pattern, the percentage of Nestin+ cells
was obviously lower (Figure 2Gi).
These findings indicated clearly that RA actually facilitated
the differentiation of neural progenitors and neural stem
cells, and as a consequence, neurons and glial cells
appeared earlier in RA-treated cultures.
3. Requirement for the RA signaling during efficient neural 
specification of ESCs
To assess the potential contribution of the RA pathway to
ESC fate, we investigated the expression of RA nuclear
receptors and RA-metabolizing enzymes in mouse ESCs.
Among RARs (RARα, -β and -γ), RXRs (RXRα, -β and -γ)
and RA-metabolizing enzymes (Raldh2  and  CYP26a1),
only  RARα, RARγ, RXRβ, Cyp26a1 and  Raldh2  were
detected readily by RT-PCR of total RNA prepared from
46C ESCs (Figure 3A). Notably, at the early stage of differ-
entiation, only the expression of RARα,  Raldh2  and
CYP26a1 showed obvious differences between RA-treated
and control cultures (Figure 3AC). This hinted that these
three molecules might play important roles in the pro-
moted neural specification effect of RA. Therefore, we
used a pharmacological approach to interfere with the
RARα pathway.
When 46C ESCs were exposed to the RARα-selective
antagonist Ro 415253 [14] during the monolayer differ-
RA stimulates accelerated neural specification Figure 1 (see previous page)
RA stimulates accelerated neural specification. 46C ESCs were cultured under monolayer differentiation conditions 
with RA (N2B27 + 10-8 M RA) or without RA (N2B27 + 0 or N2B27 + ethanol). A, B, Typical FACS profile of Sox1GFP expres-
sion at day 2. M1 is the gate used throughout to quantify the proportion Sox1GFP+ cells; C-E, Proportion of Sox1GFP+ cells at 
various time points (average of triplicates). *, p < 0.05; **, p < 0.01. D, Treatment of adherent cultures with RA after the 
appearance of the first Sox1GFP+ cells; E, Treatment of purified Sox1GFP+ cells with RA; F, Ratios of clones containing GFP+ 
cells (GFP+) or without GFP+ cells (GFP-) when cultured at clonal density. Under each culture condition, 28 clones were 
observed and counted. #, significant difference in this ratio from controls (p < 0.001, using contingency table analysis); G, 
Western blot analysis of Oct4 at day 4 under monolayer cultures; H, RT-PCR for the ESCs marker Oct4 during monolayer dif-
ferentiation. To normalize their expression to the amount of cDNA present in the sample, the cDNA for endogenous GAPDH 
was amplified; I, Q-PCR for the ESCs marker Oct4 during monolayer differentiation.BMC Cell Biology 2009, 10:57 http://www.biomedcentral.com/1471-2121/10/57
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entiation, the majority of cells failed to become Sox1GFP+
neural cells. After 92 h of differentiation, <10% of inhibi-
tor-treated cells became Sox1GFP+ compared with around
40% of cells exposed to DMSO vehicle (Figure 3D and 3E,
p < 0.001). Many inhibitor-treated cells remained Oct4+
during this period (Figure 3F and 3G). Ro 415253 also
inhibited neural differentiation in the culture without RA
(Figure 3H and 3I).
Our observations suggested that blockade of the RARα
pathway initially impeded lineage commitment, and RA
signaling was required for the efficient neural specifica-
tion of ESCs.
4. RA acts upstream of MAP kinase/ERK kinase (MEK) to 
promote neural specification
In vertebrate embryos, neural induction requires fibrob-
last growth factor (FGF) signaling through the Ras-ERK
pathway [15-17]. This also appears to be true for ESCs, in
which the initial stimulus is most likely provided by auto-
crine FGF4 [9]. To test whether RA bypassed this require-
ment, we used three pharmacological inhibitors (Figure
4). SU5402 inhibits the FGF receptor tyrosine kinase [18];
PD184352 and PD0325901 are both able to block MEK1/
2, upstream of ERK1/2 [19,20]. All of these inhibitors are
able to block neural specification of ESCs [7,21,22]. RA-
treated cells remained susceptible to blockade of neural
induction by the two MEK1/2 inhibitors, PD184352 and
PD0325901, while they were less susceptible to blockade
of neural induction by FGF receptor tyrosine kinase inhib-
itor SU5402 (Figure 4AC). Notably, SU5402 and
PD184352 markedly decreased cell number in RA-treated
monolayer cultures, while PD0325901 achieved the same
suppressive effect on ERK activation as PD184352, with-
out the dramatic side effect on cell viability or prolifera-
tion (see Additional file 4  Figure S4). In the presence of
SU5402, most cells lost the Oct4 marker of ESCs and dif-
ferentiated under the driving force of RA. However, in the
presence of the two MEK1/2 inhibitors, many cells contin-
ued to proliferate in an apparently undifferentiated Oct4+
state with minimal generation of Sox1GFP+ derivatives
(Figure 4AE).
To assess whether RA affected activation of the ERK path-
way during neural specification, we detected phosphor-
ylation of ERK by western blotting. Twelve hours after
differentiation, a higher level of phosphorylated ERK was
observed in RA-treated cultures (Figure 4F). The expres-
sion of the transcription factor Elk1, one of the down-
stream targets of ERK [23,24], was also up-regulated more
in the RA-treated cultures than in the other two control
cultures before day 3 (Figure 4G and 4H).
These findings indicated that RA acted upstream of MEK1/
2 in the neural induction cascade. RA may play a role in
enhancing ERK phosphorylation via MEK1/2 or its
upstream but not in an FGF-signaling-dependent manner.
The exact targets of RA remain to be determined.
5. Wnt signaling is involved in RA-promoted neural 
specification
Wnt signaling has been implicated in regulating neural
differentiation of ESCs. The secreted Wnt antagonist
secreted frizzled-related protein 2 (Sfrp2) is up-regulated
during neural differentiation of ESCs, and over-expression
of Sfrp2 enhances neural differentiation. Activation of the
Wnt pathway by treatment with lithium chloride (LiCl)
inhibits neural differentiation of ESCs [25]. To investigate
the effect of Wnt signaling, we added 10 mM LiCl to RA-
treated cultures. Almost no GFP+ cells were found in LiCl
and RA co-treated cultures, and most of the cells lost the
Oct4 marker of ESCs (Figure 5AC, G). CHIR99021, a
more selective inhibitor of glycogen synthase kinase 3
(GSK3) [20,26], was also used. Similar results were gained
(Figure 5DG). Q-PCR for the expression of Sfrp2 showed
that it was up-regulated at the early stage of differentiation
RA facilitates emergence of neural cells Figure 2 (see previous page)
RA facilitates emergence of neural cells. ESCs were cultured under monolayer differentiation conditions with RA 
(N2B27 + 10-8 M RA) or without RA (N2B27 + 0 or N2B27 + ethanol). A, Expression of neural markers during differentiation 
under monolayer cultures at different time points. RNA was isolated from ESCs (day 0), monolayer cultures (days 1, 3, 5 and 
10) and adult mouse brain, and analyzed by RT-PCR for expression of markers of neural progenitors/stem cells and neurons. 
To normalize their expression to the amount of cDNA present in the sample, the cDNA for endogenous GAPDH was ampli-
fied; B, C, Q-PCR for the neural marker Pax6 and Nestin during monolayer differentiation; D, F-G, Cultures at different time 
points of monolayer differentiation, shown in phase contrast or stained for markers as indicated; D, Cultures at 72 h of monol-
ayer differentiation showed that in RA-treated cultures, Sox1GFP+ and Nestin+ cells were found, while nearly no Oct4+ cells 
were detected; E, Western blot analysis of Tuj1 at day 6, of NeuN at day 8 and day 10, and of GFAP at day 10 under monol-
ayer cultures; F, At day 9, though Tuj1+ cells were also found in control cultures, the marker of mature neurons MAP2 was 
only detected in RA-treated cultures; G, At day 11, neurons (MAP2+ cells) emerged in all cultures, however, the marker of glia 
cells GFAP was only found in RA-treated cultures with a very low percentage. In control cultures, cells were dominantly Nes-
tin+, while in RA-treated cultures, the percentage of Nestin+ cells was much lower. Scale bars: D (a, b, e, f, i, j): 40 μm; D (c, g, 
k): 80 μm; D (d, h, l), F-G: 25 μm.BMC Cell Biology 2009, 10:57 http://www.biomedcentral.com/1471-2121/10/57
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Requirement for RA signaling for efficient neural specification of ESCs Figure 3
Requirement for RA signaling for efficient neural specification of ESCs. A, RT-PCR for RARs, RXRs and RA metab-
olism-relative enzymes. RNA was isolated from ESCs (day 0), monolayer cultures (days 1, 3, 5 and 10) and adult mouse brain. 
Expression of RA nuclear receptors and two RA-metabolizing enzymes (CYP26a1 and Raldh2) were analyzed by RT-PCR; B, C, 
Q-PCR for RARα and CYP26a1 during monolayer differentiation; D-G, Monolayer differentiation of 46C ESCs in RA-treated 
cultures (N2B27 + 10-8 M RA) exposed to 2 μM RARα inhibitor Ro 415253 or to equivalent amounts of DMSO diluents; D, 
Cultures of monolayer differentiation, shown in phase contrast or stained for Sox1GFP; E, Percentage of Sox1GFP+ cells scored 
by FACS. #, significant difference between inhibitor-treated cultures and DMSO-treated cultures (p < 0.001); F, Cultures of 
monolayer differentiation, shown in stained for Oct4 or combination of Oct4 and Hoechst; G, Western blot analysis of Oct4 
at day 5 under monolayer cultures; H, I, Monolayer differentiation of 46C ESCs in cultures without RA (N2B27) exposed to 2 
μM RARα inhibitor Ro 415253 or to equivalent amounts of DMSO diluents at Day6; H, Cultures of monolayer differentiation, 
shown in phase contrast or stained for Sox1GFP; I, Percentage of Sox1GFP+ cells scored by FACS; Scale bars: D, 40 μm; F, H, 80 
μm.BMC Cell Biology 2009, 10:57 http://www.biomedcentral.com/1471-2121/10/57
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RA could not bypass the requirement for ERK signaling in neural specification Figure 4
RA could not bypass the requirement for ERK signaling in neural specification. Monolayer differentiation of 46C 
ESCs in RA-treated cultures (N2B27 + 10-8 M RA) exposed to FGF receptor tyrosine kinase inhibitor SU5402 (5 μM), MEK1/2 
inhibitors PD184352 (4 μM) or PD0325901 (4 μM), or to equivalent amounts of DMSO diluents. A, Cultures of monolayer dif-
ferentiation, shown in phase contrast or stained for Sox1GFP; B, Typical FACS profile of Sox1GFP expression; C, Percentage of 
Sox1GFP+ cells scored by FACS; D, Cultures of monolayer differentiation, shown in stained for Oct4 or combination of Oct4 
and Hoechst; E, Western blot analysis of Oct4 at day 5 under monolayer cultures; F, Western blot analysis of phosphorylated 
ERK1/2 and ERK1/2 at 12 h under monolayer cultures; G, RT-PCR for Elk1, one of the targets of ERK signaling; H, Q-PCR for 
Elk1 during monolayer differentiation. *, p < 0.05; **, p < 0.01. Scale bars: A, 40 μm; D, 80 μm.BMC Cell Biology 2009, 10:57 http://www.biomedcentral.com/1471-2121/10/57
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Wnt signaling is involved in RA-promoted neural specification Figure 5
Wnt signaling is involved in RA-promoted neural specification. A-C, Monolayer differentiation of 46C ESCs in RA-
treated cultures (N2B27 + 10-8 M RA) exposed to the GSK-3 inhibitor LiCl (10 mM) or to NaCl (10 mM); A, Cultures of mon-
olayer differentiation, shown in phase contrast or stained for Sox1GFP; B, Percentage of Sox1GFP+ cells scored by FACS. #, sig-
nificant difference between inhibitor-treated cultures and NaCl-treated cultures (p < 0.001); C, Cultures of monolayer 
differentiation, shown in stained for Oct4 or combination of Oct4 and Hoechst; D-F, Monolayer differentiation of 46C ESCs in 
RA-treated cultures (N2B27 + 10-8 M RA) exposed to the GSK-3 inhibitor CHIR99021 (3 μM) or to equivalent amounts of 
DMSO diluents; D, Cultures of monolayer differentiation, shown in phase contrast or stained for Sox1GFP; E, Percentage of 
Sox1GFP+ cells scored by FACS; F, Cultures of monolayer differentiation, shown in stained for Oct4 or combination of Oct4 
and Hoechst; G, Western blot analysis of Oct4 at day 5 under monolayer cultures; H, Q-PCR for Sfrp2 during monolayer dif-
ferentiation. Scale bars: A, 40 μm; C, D, F, 80 μm.BMC Cell Biology 2009, 10:57 http://www.biomedcentral.com/1471-2121/10/57
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(Figure 5H). The two GSK3 inhibitors also inhibited neu-
ral differentiation in the culture without RA (see Addi-
tional file 5  Figure S5).
These findings showed that activation of Wnt signaling
blocked the effect of RA. However, the roles of RA and sig-
naling molecules involved in Wnt signaling still remain to
be elucidated (see discussion).
Discussion
The pluripotent ESC is a valuable in vitro model for stud-
ying the effects of various factors on cell lineage decisions
in very early embryonic stages of mammalian develop-
ment. In particular, the effects of RA signaling on the dif-
ferentiation of ESCs and neural induction have been
studied extensively. In addition to previous studies that
have shown that RA promotes neural differentiation of
ESCs [3,4,27], the present study demonstrated that RA
facilitated the emergence of neural progenitors, neural
stem cells and neurons in a monolayer culture. This is a
simple system that allows direct observation, analysis and
manipulation of the process of neural specification with-
out the confounding influence of cell aggregation, co-cul-
ture, uncharacterized media constituents, or cell selection
[9]. Furthermore, these results also demonstrated the
novel and more precise molecular mechanisms of action
of RA on neural differentiation.
1. Effects of RA on ESCs differentiation
RA and other retinoids are potent regulators of morpho-
genesis, growth and cell differentiation. RA, which is
abundant in mammalian nervous systems [28], induces
neurite outgrowth and neuronal differentiation from var-
ious sources, including ESCs [3,29], dorsal root ganglia
[30], or neuroblastoma cells [31]. RA-induced neuronal
differentiation is characterized by the expression of tissue-
specific genes, proteins, ion channels, and receptors in a
developmentally controlled manner [5].
Addition of RA promoted faster differentiation of ESCs, as
indicated by the pattern of Oct4 expression, which was
down-regulated more rapidly in RA-treated cultures, and
could not be detected after day3. This is coincident with
previous studies [32]. The expression levels of markers for
undifferentiated neural cells, i.e., Sox1, Pax6,  Nestin,
BLBP, Prominin, Olig2 and Musashi, were higher in RA-
treated cultures. As a consequence, the expression levels of
markers for neurons, i.e., Tuj1, MAP2, and NCAM, and
glial cells, i.e., GFAP were also elevated in RA-treated cul-
tures. These findings are consistent with RA-induced dif-
ferentiation of neural progenitor cells in the cell
aggregation system, as described previously [3,27,33].
The initial higher frequency of Sox1GFP+ cells in RA-treated
cultures is not caused mainly by the enhanced viability or
proliferation of neural precursor cells. After treatment
with RA, the number of purified Sox1GFP+ neural precursor
cells decreased dramatically, which indicated that RA
could not maintain the Sox1GFP+ state. This observation is
coincident with the previous studies [34]. Treatment of
adherent cultures with RA after the appearance of the first
Sox1GFP+ cells increased the number of Sox1GFP+ cells. One
explanation may be that, in monolayer culture, the speed
at which RA induced ESCs into Sox1GFP+ neural precursor
cells was faster than the speed of the loss of Sox1GFP+ cells.
2. Molecular mechanisms of action of RA on neural 
differentiation
2.1 RA signaling is involved in efficient neural specification of ESCs
It is proposed that the molecular mechanisms of action of
RA during embryogenesis in vivo involve a complex sign-
aling pathway. RA exerts its function by binding to cellular
RA-binding proteins that interact with the nuclear RA
receptors. RA binds to RARs, which normally act as ligand-
inducible transcription factors by binding as heterodimers
with RXRs to RA response elements located in regulatory
regions of target genes [35]. During in vitro differentiation
of ESCs into the neuronal lineage, RA might act in the
same way as it does in vivo. The hypothesis that in vitro and
in vivo pathways are comparable is supported by signifi-
cant up-regulation of RARα and RARβ mRNA, but rapid
down-regulation of RARγ and RXRγ mRNA during RA-
induced neuronal differentiation of mouse embryonal
carcinoma cells [36]. This suggests a role for RARα, -β, -γ
and  RXRγ  during neuroectodermal differentiation
[37,38]. However, the mechanisms whereby RA induces
neural differentiation of ESCs are not fully understood.
To demonstrate whether RA exerts its effects through RA-
related nuclear receptors and to determine which recep-
tors play more important roles in this efficient neural
specification, we detected all six isoforms of RARs and
RXRs by RT-PCR or Q-PCR. RARα, RARγ and RXRβ were
detected in ESCs. During differentiation, few differences
in the expression of RARγ  and  RXRβ  were observed
between the RA-treated and the two control groups, while
obviously different expression of RARα was observed. In
addition, the expression of RARα was up-regulated more
at day 5 than at day 3. These observations hint that RARα
may play an important role in RA-treated efficient neural
specification. Adding the RARα-selective antagonist Ro
415253 effectively blocked the neural fate of ESCs, and
many RA and Ro 415253 co-treated cells remained in an
Oct4+ state. These findings suggest that RA signaling is
indeed involved in promotion of this neural fate, and the
nuclear receptor RARα plays a key role in this effect.BMC Cell Biology 2009, 10:57 http://www.biomedcentral.com/1471-2121/10/57
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2.2 RA activates the ERK pathway during promoted neural 
specification
Studies in planaria, frog embryos and avian embryos
[17,18,39,40] have suggested a primary requirement for
FGF signaling in neural specification. FGF4 is produced in
an autocrine fashion by undifferentiated ESCs [41,42]
and activates the Ras-MEK-ERK intracellular signaling cas-
cades [22]. In our study, FGF receptor tyrosine kinase
inhibitor SU5402 was used to try to block the neural spec-
ification effect of RA. This inhibitor could not significantly
block the emergence of Sox1GFP+ neural progenitor cells in
the RA-treated monolayer cultures, although it had the
ability to inhibit the neural specification of ESCs when RA
was absent from the culture ([7], see Additional file 6  Fig-
ure S6). On the other hand, the two inhibitors PD184352
and PD0325901, both of which can block MEK1/2,
upstream of ERK1/2, were able to block neural specifica-
tion of ESCs even in the RA-treated cultures, and some
cells remained as Oct4+ cells. All of these indicate that RA
exerts its effects not through FGF signaling but requiring
the activation of MEK-ERK signaling cascades. Previous
studies have reported that RA can activate the ERK path-
way in an unknown manner [43-46]. In our study, we also
observed that phosphorylation of ERK was up-regulated at
the early stage during differentiation of ESCs in RA-treated
cultures, and the transcription factor Elk-1, one of the
downstream targets of ERK [23,24], was also more up-reg-
ulated in the RA-treated cultures than in the two control
cultures before day3. Activated ERK1/2 also mediates
phosphorylation of the MAPK sites of Smad1
(pSmad1MAPK), which inhibits the inhibitory function of
the bone morphogenetic proteins (BMP)-Smad1 pathway
on neural differentiation [47].
Based on the above, we propose that one possible mecha-
nism of how RA promotes neural lineage entry by ESCs is
that it enhances ERK phosphorylation via MEK1/2 or its
upstream but not via a mechanism that is dependent on
FGF signaling, and blockade of RA signaling may affect
the activation of the upstream of ERK1/2, which leads to
failure of neural specification of ESCs, even with the stim-
ulation of FGF signaling (Figure 6A).
2.3 Wnt signaling also plays a role in RA-promoted neural 
differentiation
Down-regulation of Wnt signaling has been shown to be
one of the mechanisms involved in RA-induced neural
differentiation of mouse ESCs. Up-regulation of Sfrp2 can
A. Interaction between RA and the ERK pathway during promoted neural specification Figure 6
A. Interaction between RA and the ERK pathway during promoted neural specification. FGF receptor tyrosine 
kinase inhibitor SU5402 and MEK1/2 inhibitors PD184352 and PD0325901, respectively suppresses neural differentiation of 
ESCs. In RA-treated cultures, PD184352, PD0325901 and RARα-selective antagonist Ro 415253 could inhibit the neural speci-
fication of ESCs, while SU5402 shows weak neural inhibition effect. RA probably enhances ERK phosphorylation via MEK1/2 or 
its upstream but not in a manner that is dependent on FGF signaling, and activated ERK1/2 mediates phosphorylation of the 
MAPK sites of Smad1 (pSmad1MAPK), which inhibits the inhibitory function of the bone morphogenetic proteins (BMPs)-Smad1 
pathway on neural differentiation. Blockade of RA signaling might affect the activation of the upstream of ERK1/2, which leads 
to failure of neural specification of ESCs even with the stimulation of FGF signaling. B. Possible roles of Wnt signaling in 
RA-promoted neural differentiation. RA promotes neural specification probably by up-regulating Sfrp2, which inhibits the 
Wnt-β-catenin anti-neural pathway. Upon adding LiCl or CHIR99021, which stimulates the β-catenin signaling and/or BMP sig-
naling through inhibition of GSK3, the suppression effects on neural specification of β-catenin pathway can be passed down 
even with the stimuli of RA. RA also may promote neural differentiation by up-regulating RAR, which may decrease β-catenin/
LEF/TCF mediated transactivation. There exists a possibility that RA may suppress the inhibition effects on neural differentia-
tion of Wnt-β-catenin pathway by sequestration of β-catenin. pSmad1GSK3 indicates phosphorylation of the GSK3 sites of 
Smad1.BMC Cell Biology 2009, 10:57 http://www.biomedcentral.com/1471-2121/10/57
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inhibit the Wnt-β-catenin anti-neural pathway. Con-
versely, adding LiCl, which inhibits GSK3 and partially
mimics Wnt signaling, can enhance the anti-neural path-
way [25]. On the other hand, GSK3 mediated-Smad1
phosphorylation can block the inhibitory effect of BMPs
on neural differentiation [47]. Therefore, inhibition of
GSK3 may also make the BMP-Smad1 pathway become
valid for inhibiting neural differentiation. Interestingly, β-
catenin, which is a key molecule in Wnt signaling, has
been shown to interact directly with RAR, and as a result
retinoids decrease activation of T-cell transcription factor
(TCF) in cultured cells in a dose-dependent manner [48].
In the present study, we found that RA up-regulated the
expression of RARα and RARβ at the early stage of differ-
entiation. We also investigated the effect of LiCl and
another GSK3 inhibitor CHIR99021. Negative effects of
Wnt pathways on neural differentiation were observed by
adding the two inhibitors to RA-treated cultures, and most
cells lost the marker of ESCs. RA also showed its effect on
up-regulating the expression of Sfrp2.
Based on the present and previous studies, RA may exert
its effects through the following mechanisms (Fig. 6B).
(1) RA promotes neural specification by up-regulating
Sfrp2. The expression of Sfrp2 is up-regulated by stimula-
tion with RA, which blocks the message passing down-
stream from Wnts [25]. Upon adding LiCl or CHIR99021,
which stimulates β-catenin and/or BMP signaling through
inhibition of GSK3, but not through Wnts, the β-catenin
pathway and/or BMP signaling can still play a part in sup-
pressing neural specification, even with the stimulus of
RA-up-regulated Sfrp2. (2) RA may promote neural differ-
entiation by up-regulating RAR, which may decrease β-
catenin-lymphoid enhancing factor (LEF)/TCF mediated
transactivation. (3) RA also may enhance the sequestra-
tion of β-catenin to suppress the anti-neural effects of the
Wnt-β-catenin pathway. However, this hypothesis needs
further evidence.
Conclusion
Our study showed that RA can promote neural lineage
entry by ESCs in adherent monolayer culture systems. We
also found that RA stimulation led to dramatic changes in
RA nuclear receptor and RA-metabolizing enzyme expres-
sion. Further study showed that these effects of RA
depended on RA signaling and its crosstalk with the ERK
and Wnt pathways. Our study showed a more limpid cir-
cumscription of the effects of RA and its pathway on neu-
ral lineage choice of mouse ESCs.
Methods
ESC culture
Mouse ESC line 46C (passage 2535), which has one allele
of Sox1 inactivated by targeted integration of a GFPirespac
cassette, was cultivated as previously described [49].
Briefly, ESCs were maintained on gelatin-coated dishes in
the absence of feeder cells in GMEM (Sigma, St. Louis,
MO) supplemented with 2 mM glutamine (Gibco, Grand
Island, NY), 0.001% β-mercaptoethanol (Gibco), 1× non-
essential amino acids (Gibco), 10% fetal bovine serum
(FBS) (Gibco), and 2,000 units/ml human recombinant
LIF (R & D Systems, Minneapolis, MN).
ESC adherent monoculture
Procedure was described in detail in [7]. Briefly, ESCs were
washed with N2B27 serum-free medium to remove serum
and then plated onto 0.1% gelatin-coated tissue culture
plastic at a density of 1 × 104 cells/cm2 in N2B27 with or
without RA (Sigma). N2B27 consists of a 1:1 ratio of
DMEM/F12 and Neurobasal media supplemented with
0.5% modified N2 (Gibco), 0.5% B27 (Gibco), and 2-
mercaptoethanol (Gibco). Medium was changed every
other day. For purifying Sox1GFP+ cells, 0.5 μg/ml puromy-
cin (Sigma) was used.
For clonal cultures assay, dissociated ESCs were plated
onto 0.1% gelatin-coated 6-well plates (Corning Incorpo-
rated, Corning, NY) at the density of 1.5 × 103 cells/well
and cultured in serum-containing ESC medium (3 ml/
well) plus LIF. At this density, more than 90% of colonies
derived from single cells. After 2 days, medium was
replaced with serum-free neural differentiation medium
N2B27. Medium was renewed with fresh N2B27 every
other day. After 2 days culture in N2B27 medium, total
colonies and colonies containing Sox1GFP+ cells were
counted.
Cells were counted by using a hemocytometer.
Immunofluorescence and FACS
Cells were fixed in 4% paraformaldehyde and incubated
for 1 h in blocking buffer (PBS, 10% FBS, and 0.1% Triton
X-100). Primary antibodies were diluted in blocking
buffer and applied overnight at 4°C. After three washes in
PBS, secondary antibodies conjugated to TRITC (tetrame-
thylrhodamine isothiocyanate) (Vector, Burlingame, CA)
were diluted at 1: 200 in blocking buffer and applied for
1 h at room temperature. The cells were washed at least
three times in PBS and visualized on an Olympus inverted
fluorescence microscope. For nuclear counter staining,
nuclei were stained with bisbenzimide (Hoechst 33342,
10 μM, Sigma).
Primary antibodies were obtained from the following
sources: Oct4 (1: 500, Santa Cruz Biotechnology, Santa
Cruz, CA), nestin (1:200, Chemicon, Temecula, CA), Tuj1
(1:200, R & D Systems), MAP2 (1: 200, Sigma), GFAP
(1:400, Chemicon).BMC Cell Biology 2009, 10:57 http://www.biomedcentral.com/1471-2121/10/57
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FACS analysis was performed using a Becton-Dickinson
(Palo Alto, CA) FACS Calibur flow cytometer.
RT-PCR and Q-PCR analysis
RT-PCR analysis of at least three independent cultures was
performed in most of the experiments, and similar results
were obtained.
RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA),
DNase I-digested (Invitrogen), and column-purified
(RNeasy MinElute Cleanup; Qiagen, Valencia, CA). First-
strand cDNA was synthesized using M-MLV Reverse Tran-
scriptase (Invitrogen). To analyze relative expression of
different mRNAs, the amount of cDNA was normalized
based on the signals from ubiquitously expressed GAPDH
mRNA. To provide negative controls and exclude contam-
ination by genomic DNA, the reverse transcriptase was
omitted in the cDNA synthesis step, and the samples were
subjected to the PCR reaction in the same manner with
primer sets for GAPDH, and were indicated at the bottom
of each figure as RT (-). Primer sequences and PCR cycling
conditions could be found in the Additional file 7  Table
S1.
Q-PCR was performed with Power SYBR Green PCR Mas-
ter Mix (Applied Biosystems, Foster City, CA) according to
manufacturer's instructions. Signals were detected with an
ABI7300 Real-Time PCR System (Applied Biosystems).
The relative expression level was determine by the 2-delta Ct
method and normalized against ribosomal protein L19
(RPL19). Primer sequences could be found in the Addi-
tional file 8  Table S2.
Western blot analysis
Cells and tissues were lysed in a lysis buffer (20 mM Tris-
HCl, pH 7.4, 2% Triton X-100, 10 mM EDTA, 5 mM NaF
and 1 mM sodium orthovanadate). Protein concentration
was determined by BCA assay (Pierce, Rockford, IL). Then
proteins were resolved in 12% SDS polyacrylamide gels
and transferred onto nitrocellulose membranes. The
membranes were then incubated overnight at 4°C in
blocking solution containing 5% nonfat dry milk in PBS
with 0.1% Tween-20. Subsequently the membranes were
incubated with primary antibody against Oct-4 (1:1000,
Santa Cruz), ERK1/2, phosphor-ERK1/2 (both 1:500, Cell
Signaling Technology, MA), Neuronal Nuclei (NeuN,
1:200, Chemicon), β-actin (1:2000, Biovision, Mountain
View, CA) or alpha Tubulin (1:2000, Sigma) followed by
incubation with HRP (horseradish peroxidase)-conju-
gated second antibodies. Detection of HRP was per-
formed by SuperSignal West Pico Chemiluminescent
Substrate (Pierce).
Pharmacological reagents
Ro 415253 (Biomol, Plymouth Meeting, PA) was used at
1  μM. PD184352, PD0325901 and CHIR99021 (kind
gifts of Professor Qilong Ying, University of Southern Cal-
ifornia, USA) was used at a concentration of 4 μM, 4 μM
and 3 μM respectively. SU5402 (Calbiochem, San Diego,
CA) was used at 5 μM. LiCl (Sigma) was used at 10 mM.
Data analysis
The statistics were analyzed by STAT 8.0 software. For
comparisons of two conditions, the Student's t test was
used. All data were expressed as mean ± standard error of
mean (S.E.M.).
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